Recruiting IgA Nephropathy Studies in Shelby
About IgA Nephropathy Clinical Trials in Shelby
IgA nephropathy is the most common form of glomerulonephritis worldwide, caused by deposits of immunoglobulin A in the kidneys. It can lead to kidney inflammation and progressive kidney damage. Treatment includes blood pressure management, immunosuppression, and newer targeted therapies.
There are currently 2 iga nephropathy clinical trials recruiting participants in Shelby, MI. These studies are seeking a combined 65 participants. Research is being sponsored by ADARx Pharmaceuticals, Inc., Biohaven Therapeutics Ltd.. Clinical trial participation is free and participants receive study-related medical care at no cost.
IgA Nephropathy Clinical Trials in Shelby — FAQ
Are there iga nephropathy clinical trials in Shelby?
Yes, there are 2 iga nephropathy clinical trials currently recruiting in Shelby, MI. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Shelby?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Shelby research site will contact you about next steps.
Are clinical trials in Shelby free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Shelby studies also compensate for your time and travel.
What iga nephropathy treatments are being tested?
The 2 active trials in Shelby are testing new therapies including novel drugs, biologics, and treatment approaches for iga nephropathy.
Data updated July 13, 2026 from ClinicalTrials.gov